

Global Cholangiocarcinoma Pipeline Market Research Report 2023

<https://marketpublishers.com/r/G9E194936904EN.html>

Date: October 2023

Pages: 112

Price: US\$ 2,900.00 (Single User License)

ID: G9E194936904EN

Abstracts

This report aims to provide a comprehensive presentation of the global market for Cholangiocarcinoma Pipeline, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cholangiocarcinoma Pipeline.

The Cholangiocarcinoma Pipeline market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cholangiocarcinoma Pipeline market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cholangiocarcinoma Pipeline companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

Medivir

Hutchison Medipharma

Agios Pharmaceuticals

TransThera Biosciences

Senhwa Biosciences

Eisai

EMD Serono

Taiho Oncology

Sirnaomics

RedHill Biopharma

MacroGenics

Chia Tai Tianqing Pharmaceutical Group

Sirtex Medical

Delcath Systems Inc.

Innovent Biologics

PCI Biotech AS

Basilea Pharmaceutica

QED Therapeutics

Bristol-Myers Squibb

AstraZeneca

Eli Lilly and Company

Toray Industries

Bold Therapeutics

Segment by Type

Mono

Combination

Segment by Application

Gene Therapy

Stem Cell Therapy

Gene Therapy

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cholangiocarcinoma Pipeline companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cholangiocarcinoma Pipeline Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Mono

1.2.3 Combination

1.3 Market by Application

1.3.1 Global Cholangiocarcinoma Pipeline Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Gene Therapy

1.3.3 Stem Cell Therapy

1.3.4 Gene Therapy

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Cholangiocarcinoma Pipeline Market Perspective (2018-2029)

2.2 Cholangiocarcinoma Pipeline Growth Trends by Region

2.2.1 Global Cholangiocarcinoma Pipeline Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Cholangiocarcinoma Pipeline Historic Market Size by Region (2018-2023)

2.2.3 Cholangiocarcinoma Pipeline Forecasted Market Size by Region (2024-2029)

2.3 Cholangiocarcinoma Pipeline Market Dynamics

2.3.1 Cholangiocarcinoma Pipeline Industry Trends

2.3.2 Cholangiocarcinoma Pipeline Market Drivers

2.3.3 Cholangiocarcinoma Pipeline Market Challenges

2.3.4 Cholangiocarcinoma Pipeline Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Cholangiocarcinoma Pipeline Players by Revenue

3.1.1 Global Top Cholangiocarcinoma Pipeline Players by Revenue (2018-2023)

3.1.2 Global Cholangiocarcinoma Pipeline Revenue Market Share by Players

(2018-2023)

3.2 Global Cholangiocarcinoma Pipeline Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Cholangiocarcinoma Pipeline Revenue

3.4 Global Cholangiocarcinoma Pipeline Market Concentration Ratio

3.4.1 Global Cholangiocarcinoma Pipeline Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cholangiocarcinoma Pipeline Revenue in 2022

3.5 Cholangiocarcinoma Pipeline Key Players Head office and Area Served

3.6 Key Players Cholangiocarcinoma Pipeline Product Solution and Service

3.7 Date of Enter into Cholangiocarcinoma Pipeline Market

3.8 Mergers & Acquisitions, Expansion Plans

4 CHOLANGIOCARCINOMA PIPELINE BREAKDOWN DATA BY TYPE

4.1 Global Cholangiocarcinoma Pipeline Historic Market Size by Type (2018-2023)

4.2 Global Cholangiocarcinoma Pipeline Forecasted Market Size by Type (2024-2029)

5 CHOLANGIOCARCINOMA PIPELINE BREAKDOWN DATA BY APPLICATION

5.1 Global Cholangiocarcinoma Pipeline Historic Market Size by Application (2018-2023)

5.2 Global Cholangiocarcinoma Pipeline Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Cholangiocarcinoma Pipeline Market Size (2018-2029)

6.2 North America Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Cholangiocarcinoma Pipeline Market Size by Country (2018-2023)

6.4 North America Cholangiocarcinoma Pipeline Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Cholangiocarcinoma Pipeline Market Size (2018-2029)

7.2 Europe Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2018 VS

2022 VS 2029

7.3 Europe Cholangiocarcinoma Pipeline Market Size by Country (2018-2023)

7.4 Europe Cholangiocarcinoma Pipeline Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Cholangiocarcinoma Pipeline Market Size (2018-2029)

8.2 Asia-Pacific Cholangiocarcinoma Pipeline Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2018-2023)

8.4 Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Cholangiocarcinoma Pipeline Market Size (2018-2029)

9.2 Latin America Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Cholangiocarcinoma Pipeline Market Size by Country (2018-2023)

9.4 Latin America Cholangiocarcinoma Pipeline Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Cholangiocarcinoma Pipeline Market Size (2018-2029)

10.2 Middle East & Africa Cholangiocarcinoma Pipeline Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2018-2023)

10.4 Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Medivir

11.1.1 Medivir Company Detail

11.1.2 Medivir Business Overview

11.1.3 Medivir Cholangiocarcinoma Pipeline Introduction

11.1.4 Medivir Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)

11.1.5 Medivir Recent Development

11.2 Hutchison Medipharma

11.2.1 Hutchison Medipharma Company Detail

11.2.2 Hutchison Medipharma Business Overview

11.2.3 Hutchison Medipharma Cholangiocarcinoma Pipeline Introduction

11.2.4 Hutchison Medipharma Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)

11.2.5 Hutchison Medipharma Recent Development

11.3 Agios Pharmaceuticals

11.3.1 Agios Pharmaceuticals Company Detail

11.3.2 Agios Pharmaceuticals Business Overview

11.3.3 Agios Pharmaceuticals Cholangiocarcinoma Pipeline Introduction

11.3.4 Agios Pharmaceuticals Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)

11.3.5 Agios Pharmaceuticals Recent Development

11.4 TransThera Biosciences

11.4.1 TransThera Biosciences Company Detail

11.4.2 TransThera Biosciences Business Overview

11.4.3 TransThera Biosciences Cholangiocarcinoma Pipeline Introduction

11.4.4 TransThera Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)

11.4.5 TransThera Biosciences Recent Development

11.5 Senhwa Biosciences

11.5.1 Senhwa Biosciences Company Detail

- 11.5.2 Senhwa Biosciences Business Overview
- 11.5.3 Senhwa Biosciences Cholangiocarcinoma Pipeline Introduction
- 11.5.4 Senhwa Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
- 11.5.5 Senhwa Biosciences Recent Development
- 11.6 Eisai
 - 11.6.1 Eisai Company Detail
 - 11.6.2 Eisai Business Overview
 - 11.6.3 Eisai Cholangiocarcinoma Pipeline Introduction
 - 11.6.4 Eisai Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.6.5 Eisai Recent Development
- 11.7 EMD Serono
 - 11.7.1 EMD Serono Company Detail
 - 11.7.2 EMD Serono Business Overview
 - 11.7.3 EMD Serono Cholangiocarcinoma Pipeline Introduction
 - 11.7.4 EMD Serono Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.7.5 EMD Serono Recent Development
- 11.8 Taiho Oncology
 - 11.8.1 Taiho Oncology Company Detail
 - 11.8.2 Taiho Oncology Business Overview
 - 11.8.3 Taiho Oncology Cholangiocarcinoma Pipeline Introduction
 - 11.8.4 Taiho Oncology Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.8.5 Taiho Oncology Recent Development
- 11.9 Sirnaomics
 - 11.9.1 Sirnaomics Company Detail
 - 11.9.2 Sirnaomics Business Overview
 - 11.9.3 Sirnaomics Cholangiocarcinoma Pipeline Introduction
 - 11.9.4 Sirnaomics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.9.5 Sirnaomics Recent Development
- 11.10 RedHill Biopharma
 - 11.10.1 RedHill Biopharma Company Detail
 - 11.10.2 RedHill Biopharma Business Overview
 - 11.10.3 RedHill Biopharma Cholangiocarcinoma Pipeline Introduction
 - 11.10.4 RedHill Biopharma Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.10.5 RedHill Biopharma Recent Development
- 11.11 MacroGenics
 - 11.11.1 MacroGenics Company Detail

- 11.11.2 MacroGenics Business Overview
- 11.11.3 MacroGenics Cholangiocarcinoma Pipeline Introduction
- 11.11.4 MacroGenics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
- 11.11.5 MacroGenics Recent Development
- 11.12 Chia Tai Tianqing Pharmaceutical Group
 - 11.12.1 Chia Tai Tianqing Pharmaceutical Group Company Detail
 - 11.12.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
 - 11.12.3 Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Introduction
 - 11.12.4 Chia Tai Tianqing Pharmaceutical Group Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.12.5 Chia Tai Tianqing Pharmaceutical Group Recent Development
- 11.13 Sirtex Medical
 - 11.13.1 Sirtex Medical Company Detail
 - 11.13.2 Sirtex Medical Business Overview
 - 11.13.3 Sirtex Medical Cholangiocarcinoma Pipeline Introduction
 - 11.13.4 Sirtex Medical Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.13.5 Sirtex Medical Recent Development
- 11.14 Delcath Systems Inc.
 - 11.14.1 Delcath Systems Inc. Company Detail
 - 11.14.2 Delcath Systems Inc. Business Overview
 - 11.14.3 Delcath Systems Inc. Cholangiocarcinoma Pipeline Introduction
 - 11.14.4 Delcath Systems Inc. Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.14.5 Delcath Systems Inc. Recent Development
- 11.15 Innovent Biologics
 - 11.15.1 Innovent Biologics Company Detail
 - 11.15.2 Innovent Biologics Business Overview
 - 11.15.3 Innovent Biologics Cholangiocarcinoma Pipeline Introduction
 - 11.15.4 Innovent Biologics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.15.5 Innovent Biologics Recent Development
- 11.16 PCI Biotech AS
 - 11.16.1 PCI Biotech AS Company Detail
 - 11.16.2 PCI Biotech AS Business Overview
 - 11.16.3 PCI Biotech AS Cholangiocarcinoma Pipeline Introduction
 - 11.16.4 PCI Biotech AS Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)

- 11.16.5 PCI Biotech AS Recent Development
- 11.17 Basilea Pharmaceutica
 - 11.17.1 Basilea Pharmaceutica Company Detail
 - 11.17.2 Basilea Pharmaceutica Business Overview
 - 11.17.3 Basilea Pharmaceutica Cholangiocarcinoma Pipeline Introduction
 - 11.17.4 Basilea Pharmaceutica Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.17.5 Basilea Pharmaceutica Recent Development
- 11.18 QED Therapeutics
 - 11.18.1 QED Therapeutics Company Detail
 - 11.18.2 QED Therapeutics Business Overview
 - 11.18.3 QED Therapeutics Cholangiocarcinoma Pipeline Introduction
 - 11.18.4 QED Therapeutics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.18.5 QED Therapeutics Recent Development
- 11.19 Bristol-Myers Squibb
 - 11.19.1 Bristol-Myers Squibb Company Detail
 - 11.19.2 Bristol-Myers Squibb Business Overview
 - 11.19.3 Bristol-Myers Squibb Cholangiocarcinoma Pipeline Introduction
 - 11.19.4 Bristol-Myers Squibb Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.19.5 Bristol-Myers Squibb Recent Development
- 11.20 AstraZeneca
 - 11.20.1 AstraZeneca Company Detail
 - 11.20.2 AstraZeneca Business Overview
 - 11.20.3 AstraZeneca Cholangiocarcinoma Pipeline Introduction
 - 11.20.4 AstraZeneca Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.20.5 AstraZeneca Recent Development
- 11.21 Eli Lilly and Company
 - 11.21.1 Eli Lilly and Company Company Detail
 - 11.21.2 Eli Lilly and Company Business Overview
 - 11.21.3 Eli Lilly and Company Cholangiocarcinoma Pipeline Introduction
 - 11.21.4 Eli Lilly and Company Revenue in Cholangiocarcinoma Pipeline Business (2018-2023)
 - 11.21.5 Eli Lilly and Company Recent Development
- 11.22 Toray Industries
 - 11.22.1 Toray Industries Company Detail
 - 11.22.2 Toray Industries Business Overview
 - 11.22.3 Toray Industries Cholangiocarcinoma Pipeline Introduction

11.22.4 Toray Industries Revenue in Cholangiocarcinoma Pipeline Business
(2018-2023)

11.22.5 Toray Industries Recent Development

11.23 Bold Therapeutics

11.23.1 Bold Therapeutics Company Detail

11.23.2 Bold Therapeutics Business Overview

11.23.3 Bold Therapeutics Cholangiocarcinoma Pipeline Introduction

11.23.4 Bold Therapeutics Revenue in Cholangiocarcinoma Pipeline Business
(2018-2023)

11.23.5 Bold Therapeutics Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Cholangiocarcinoma Pipeline Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Mono

Table 3. Key Players of Combination

Table 4. Global Cholangiocarcinoma Pipeline Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 5. Global Cholangiocarcinoma Pipeline Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global Cholangiocarcinoma Pipeline Market Size by Region (2018-2023) & (US\$ Million)

Table 7. Global Cholangiocarcinoma Pipeline Market Share by Region (2018-2023)

Table 8. Global Cholangiocarcinoma Pipeline Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 9. Global Cholangiocarcinoma Pipeline Market Share by Region (2024-2029)

Table 10. Cholangiocarcinoma Pipeline Market Trends

Table 11. Cholangiocarcinoma Pipeline Market Drivers

Table 12. Cholangiocarcinoma Pipeline Market Challenges

Table 13. Cholangiocarcinoma Pipeline Market Restraints

Table 14. Global Cholangiocarcinoma Pipeline Revenue by Players (2018-2023) & (US\$ Million)

Table 15. Global Cholangiocarcinoma Pipeline Market Share by Players (2018-2023)

Table 16. Global Top Cholangiocarcinoma Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cholangiocarcinoma Pipeline as of 2022)

Table 17. Ranking of Global Top Cholangiocarcinoma Pipeline Companies by Revenue (US\$ Million) in 2022

Table 18. Global 5 Largest Players Market Share by Cholangiocarcinoma Pipeline Revenue (CR5 and HHI) & (2018-2023)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Cholangiocarcinoma Pipeline Product Solution and Service

Table 21. Date of Enter into Cholangiocarcinoma Pipeline Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Cholangiocarcinoma Pipeline Market Size by Type (2018-2023) & (US\$ Million)

Table 24. Global Cholangiocarcinoma Pipeline Revenue Market Share by Type

(2018-2023)

Table 25. Global Cholangiocarcinoma Pipeline Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 26. Global Cholangiocarcinoma Pipeline Revenue Market Share by Type (2024-2029)

Table 27. Global Cholangiocarcinoma Pipeline Market Size by Application (2018-2023) & (US\$ Million)

Table 28. Global Cholangiocarcinoma Pipeline Revenue Market Share by Application (2018-2023)

Table 29. Global Cholangiocarcinoma Pipeline Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 30. Global Cholangiocarcinoma Pipeline Revenue Market Share by Application (2024-2029)

Table 31. North America Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 32. North America Cholangiocarcinoma Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 33. North America Cholangiocarcinoma Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 34. Europe Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. Europe Cholangiocarcinoma Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 36. Europe Cholangiocarcinoma Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Asia-Pacific Cholangiocarcinoma Pipeline Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2018-2023) & (US\$ Million)

Table 39. Asia-Pacific Cholangiocarcinoma Pipeline Market Size by Region (2024-2029) & (US\$ Million)

Table 40. Latin America Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Latin America Cholangiocarcinoma Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 42. Latin America Cholangiocarcinoma Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 43. Middle East & Africa Cholangiocarcinoma Pipeline Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Middle East & Africa Cholangiocarcinoma Pipeline Market Size by Country (2024-2029) & (US\$ Million)

Table 46. Medivir Company Detail

Table 47. Medivir Business Overview

Table 48. Medivir Cholangiocarcinoma Pipeline Product

Table 49. Medivir Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)

Table 50. Medivir Recent Development

Table 51. Hutchison Medipharma Company Detail

Table 52. Hutchison Medipharma Business Overview

Table 53. Hutchison Medipharma Cholangiocarcinoma Pipeline Product

Table 54. Hutchison Medipharma Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)

Table 55. Hutchison Medipharma Recent Development

Table 56. Agios Pharmaceuticals Company Detail

Table 57. Agios Pharmaceuticals Business Overview

Table 58. Agios Pharmaceuticals Cholangiocarcinoma Pipeline Product

Table 59. Agios Pharmaceuticals Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)

Table 60. Agios Pharmaceuticals Recent Development

Table 61. TransThera Biosciences Company Detail

Table 62. TransThera Biosciences Business Overview

Table 63. TransThera Biosciences Cholangiocarcinoma Pipeline Product

Table 64. TransThera Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)

Table 65. TransThera Biosciences Recent Development

Table 66. Senhwa Biosciences Company Detail

Table 67. Senhwa Biosciences Business Overview

Table 68. Senhwa Biosciences Cholangiocarcinoma Pipeline Product

Table 69. Senhwa Biosciences Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)

Table 70. Senhwa Biosciences Recent Development

Table 71. Eisai Company Detail

Table 72. Eisai Business Overview

Table 73. Eisai Cholangiocarcinoma Pipeline Product

Table 74. Eisai Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)

- Table 75. Eisai Recent Development
- Table 76. EMD Serono Company Detail
- Table 77. EMD Serono Business Overview
- Table 78. EMD Serono Cholangiocarcinoma Pipeline Product
- Table 79. EMD Serono Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 80. EMD Serono Recent Development
- Table 81. Taiho Oncology Company Detail
- Table 82. Taiho Oncology Business Overview
- Table 83. Taiho Oncology Cholangiocarcinoma Pipeline Product
- Table 84. Taiho Oncology Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 85. Taiho Oncology Recent Development
- Table 86. Sirnaomics Company Detail
- Table 87. Sirnaomics Business Overview
- Table 88. Sirnaomics Cholangiocarcinoma Pipeline Product
- Table 89. Sirnaomics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 90. Sirnaomics Recent Development
- Table 91. RedHill Biopharma Company Detail
- Table 92. RedHill Biopharma Business Overview
- Table 93. RedHill Biopharma Cholangiocarcinoma Pipeline Product
- Table 94. RedHill Biopharma Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 95. RedHill Biopharma Recent Development
- Table 96. MacroGenics Company Detail
- Table 97. MacroGenics Business Overview
- Table 98. MacroGenics Cholangiocarcinoma Pipeline Product
- Table 99. MacroGenics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 100. MacroGenics Recent Development
- Table 101. Chia Tai Tianqing Pharmaceutical Group Company Detail
- Table 102. Chia Tai Tianqing Pharmaceutical Group Business Overview
- Table 103. Chia Tai Tianqing Pharmaceutical Group Cholangiocarcinoma Pipeline Product
- Table 104. Chia Tai Tianqing Pharmaceutical Group Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 105. Chia Tai Tianqing Pharmaceutical Group Recent Development
- Table 106. Sirtex Medical Company Detail

- Table 107. Sirtex Medical Business Overview
- Table 108. Sirtex Medical Cholangiocarcinoma Pipeline Product
- Table 109. Sirtex Medical Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 110. Sirtex Medical Recent Development
- Table 111. Delcath Systems Inc. Company Detail
- Table 112. Delcath Systems Inc. Business Overview
- Table 113. Delcath Systems Inc. Cholangiocarcinoma Pipeline Product
- Table 114. Delcath Systems Inc. Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 115. Delcath Systems Inc. Recent Development
- Table 116. Innovent Biologics Company Detail
- Table 117. Innovent Biologics Business Overview
- Table 118. Innovent Biologics Cholangiocarcinoma Pipeline Product
- Table 119. Innovent Biologics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 120. Innovent Biologics Recent Development
- Table 121. PCI Biotech AS Company Detail
- Table 122. PCI Biotech AS Business Overview
- Table 123. PCI Biotech AS Cholangiocarcinoma Pipeline Product
- Table 124. PCI Biotech AS Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 125. PCI Biotech AS Recent Development
- Table 126. Basilea Pharmaceutica Company Detail
- Table 127. Basilea Pharmaceutica Business Overview
- Table 128. Basilea Pharmaceutica Cholangiocarcinoma Pipeline Product
- Table 129. Basilea Pharmaceutica Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 130. Basilea Pharmaceutica Recent Development
- Table 131. QED Therapeutics Company Detail
- Table 132. QED Therapeutics Business Overview
- Table 133. QED Therapeutics Cholangiocarcinoma Pipeline Product
- Table 134. QED Therapeutics Revenue in Cholangiocarcinoma Pipeline Business (2018-2023) & (US\$ Million)
- Table 135. QED Therapeutics Recent Development
- Table 136. Bristol-Myers Squibb Company Detail
- Table 137. Bristol-Myers Squibb Business Overview
- Table 138. Bristol-Myers Squibb Cholangiocarcinoma Pipeline Product
- Table 139. Bristol-Myers Squibb Revenue in Cholangiocarcinoma Pipeline Business

(2018-2023) & (US\$ Million)

Table 140. Bristol-Myers Squibb Recent Development

Table 141. AstraZeneca Company Detail

Table 142. AstraZeneca Business Overview

Table 143. AstraZeneca Cholangiocarcinoma Pipeline Product

Table 144. AstraZeneca Revenue in Cholangiocarcinoma Pipeline Business

(2018-2023) & (US\$ Million)

Table 145. AstraZeneca Recent Development

Table 146. Eli Lilly and Company Company Detail

Table 147. Eli Lilly and Company Business Overview

Table 148. Eli Lilly and Company Cholangiocarcinoma Pipeline Product

Table 149. Eli Lilly and Company Revenue in Cholangiocarcinoma Pipeline Business

(2018-2023) & (US\$ Million)

Table 150. Eli Lilly and Company Recent Development

Table 151. Toray Industries Company Detail

Table 152. Toray Industries Business Overview

Table 153. Toray Industries Cholangiocarcinoma Pipeline Product

Table 154. Toray Industries Revenue in Cholangiocarcinoma Pipeline Business

(2018-2023) & (US\$ Million)

Table 155. Toray Industries Recent Development

Table 156. Bold Therapeutics Company Detail

Table 157. Bold Therapeutics Business Overview

Table 158. Bold Therapeutics Cholangiocarcinoma Pipeline Product

Table 159. Bold Therapeutics Revenue in Cholangiocarcinoma Pipeline Business

(2018-2023) & (US\$ Million)

Table 160. Bold Therapeutics Recent Development

Table 161. Research Programs/Design for This Report

Table 162. Key Data Information from Secondary Sources

Table 163. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Cholangiocarcinoma Pipeline Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Cholangiocarcinoma Pipeline Market Share by Type: 2022 VS 2029

Figure 3. Mono Features

Figure 4. Combination Features

Figure 5. Global Cholangiocarcinoma Pipeline Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 6. Global Cholangiocarcinoma Pipeline Market Share by Application: 2022 VS 2029

Figure 7. Gene Therapy Case Studies

Figure 8. Stem Cell Therapy Case Studies

Figure 9. Gene Therapy Case Studies

Figure 10. Cholangiocarcinoma Pipeline Report Years Considered

Figure 11. Global Cholangiocarcinoma Pipeline Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 12. Global Cholangiocarcinoma Pipeline Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 13. Global Cholangiocarcinoma Pipeline Market Share by Region: 2022 VS 2029

Figure 14. Global Cholangiocarcinoma Pipeline Market Share by Players in 2022

Figure 15. Global Top Cholangiocarcinoma Pipeline Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cholangiocarcinoma Pipeline as of 2022)

Figure 16. The Top 10 and 5 Players Market Share by Cholangiocarcinoma Pipeline Revenue in 2022

Figure 17. North America Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 18. North America Cholangiocarcinoma Pipeline Market Share by Country (2018-2029)

Figure 19. United States Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. Canada Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. Europe Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 22. Europe Cholangiocarcinoma Pipeline Market Share by Country (2018-2029)

Figure 23. Germany Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. France Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. U.K. Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Italy Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Russia Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Nordic Countries Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Asia-Pacific Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Asia-Pacific Cholangiocarcinoma Pipeline Market Share by Region (2018-2029)

Figure 31. China Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Japan Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. South Korea Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Southeast Asia Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. India Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Australia Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Latin America Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Latin America Cholangiocarcinoma Pipeline Market Share by Country (2018-2029)

Figure 39. Mexico Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Brazil Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Middle East & Africa Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Middle East & Africa Cholangiocarcinoma Pipeline Market Share by Country

(2018-2029)

Figure 43. Turkey Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Saudi Arabia Cholangiocarcinoma Pipeline Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Medivir Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 46. Hutchison Medipharma Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 47. Agios Pharmaceuticals Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 48. TransThera Biosciences Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 49. Senhwa Biosciences Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 50. Eisai Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 51. EMD Serono Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 52. Taiho Oncology Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 53. Sirnaomics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 54. RedHill Biopharma Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 55. MacroGenics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 56. Chia Tai Tianqing Pharmaceutical Group Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 57. Sirtex Medical Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 58. Delcath Systems Inc. Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 59. Innovent Biologics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 60. PCI Biotech AS Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 61. Basilea Pharmaceutica Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 62. QED Therapeutics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 64. AstraZeneca Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 65. Eli Lilly and Company Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 66. Toray Industries Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 67. Bold Therapeutics Revenue Growth Rate in Cholangiocarcinoma Pipeline Business (2018-2023)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

I would like to order

Product name: Global Cholangiocarcinoma Pipeline Market Research Report 2023

Product link: <https://marketpublishers.com/r/G9E194936904EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9E194936904EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970